Patient-derived Xenograft Model Market Size To Reach $505.3 Million By 2030

Patient-derived Xenograft Model Market Growth & Trends

The global patient-derived xenograft model market size is expected to reach USD 505.3 million in 2030 and is projected to grow at a CAGR of 9.64% from 2025 to 2030. Growing burden of cancer, which is promoting the demand for new treatment options, along with significant demand for personalized therapies worldwide will boost the growth of the industry. Patient-derived Xenograft (PDX) models have garnered increasing awareness during the past decade. These types are typically characterized by the introduction of fresh immunodeficient mice with patient-derived tumor tissues. These models have been used with efficacy in preclinical studies to identify prospective biomarkers for drug response and resistance, as well as to monitor the development of tumors in therapy response. The concept of a co-clinical study, which involves using several models at once-referred to as “Avatar models”-has recently grown in popularity and has been expanded to incorporate PDX models.

Moreover, PDX models were used in a few prospective trials to direct therapeutic therapy decisions for a limited number of patients with confirmed extended survival. The COVID-19 pandemic had a negative impact on the industry. It disrupted the clinical trials and also reduced the productivity of pharmaceutical & biopharmaceutical companies. According to research by Avantor Sciences, 70% of global clinical trials were disrupted as of July 2020. 369 trials related to oncology had been delayed in the USA alone, central nervous system trials at 223, gastrointestinal trials at 116, and cardiovascular trials at 99. Despite COVID-19, the rising number of cancer cases & increased R&D activities by pharmaceutical companies will contribute to the growth of the market. For instance, as per the GLOBOCAN Report 2020, 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020. The majorly impacted cancers were breast, lung, colorectal, and prostate cancer.

 Request a free sample copy or view report summary: Patient-derived Xenograft Model Market Report

Patient-derived Xenograft Model Market Report Highlights

• The breast cancer segment dominated with 31.7% of the revenue share in 2024 owing to increasing cases of breast cancer globally.

• For instance, female breast cancer is expected 2.3 million new cases & has surpassed lung cancer as the most prevalent disease diagnosed.

• The mice model segment dominated the market in 2024. Mice are the most commonly used species for xenograft studies due to their well-established immunodeficient strains, cost-effectiveness, and ease of handling.

• The CRO and CDMO segment dominated the market in 2024 owing to increasing outsourcing activities by pharmaceutical and biotechnology companies for research and development activities.

• Pharmaceutical and biopharmaceutical companies are projected to witness considerable growth from 2025 to 2030 owing to the increasing demand for more accurate and reliable preclinical models to advance drug discovery and development.

• North America patient-derived xenograft model market dominated the global market and accounted for a 44.6% share in 2024.

Patient-derived Xenograft Model Market Segmentation

Grand View Research has segmented the global patient-derived xenograft model market report based on tumor type, model type, end use, and region:

Patient-derived Xenograft Model Tumor Type Outlook (Revenue, USD Million, 2018 - 2030)

• Lung Cancer

• Pancreatic Cancer

• Prostate Cancer

• Breast Cancer

• Others

Patient-derived Xenograft Model Model Type Outlook (Revenue, USD Million, 2018 - 2030)

• Mice Model

• Rat Model

Patient-derived Xenograft Model End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical and Biopharmaceutical Companies

• Academic and Research Institutes

• CRO’s and CDMO’s

Patient-derived Xenograft Model Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Norway

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Patient-derived Xenograft Model Market

• Charles River Laboratories

• The Jackson Laboratory

• Crown Bioscience

• Altogen Labs

• Envigo

• WuXi AppTec

• Oncodesign

• Hera Biolabs

• XenTech

• Abnova Corp.